DQ-113 was compared in vitro to sitafloxacin, moxifloxacin, levofloxacin, and ciprofloxacin for potential to select mutational resistance in multiresistant staphylococci, pneumococci, and enterococci. Its ability to select less-susceptible mutants varied according to species, being lowest with staphylococci, intermediate with pneumococci, and greatest with enterococci. DQ-113 is an investigational fluoroquinolone with enhanced anti-gram-positive activity ( Fig. 1) (6, 8, 10) . We report investigations into its potential to select less-susceptible mutants from clinical isolates of Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus spp.
DQ-113 is an investigational fluoroquinolone with enhanced anti-gram-positive activity ( Fig. 1) (6, 8, 10) . We report investigations into its potential to select less-susceptible mutants from clinical isolates of Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus spp.
Single-step mutational frequencies were determined after exposure of approximately 10 7 to 10 9 CFU of five clinical isolates each of methicillin-susceptible S. aureus (MSSA), methicillinresistant S. aureus (MRSA), penicillin-resistant S. pneumoniae (PRSP), and vancomycin-resistant Enterococcus spp. (VRE) (one E. faecalis and four E. faecium strains) to DQ-113, sitafloxacin, moxifloxacin, ciprofloxacin, and levofloxacin (powders provided by their manufacturers) at the MIC, and two, four, and eight times the MIC in appropriate media for 48 to 72 h at 35°C in air (5% CO 2 for S. pneumoniae) as previously described (1) . Mutants were also selected at subinhibitory fluoroquinolone concentrations by the agar gradient plate method of Bryson and Szybalski (2) after five passages on drug-containing media. The MRSA strains were relatively susceptible to fluoroquinolones and not representative of frequently encountered nosocomial strains. Antibiotic susceptibilities were determined by the Clinical and Laboratory Standards Institute (CLSI) agar dilution methodology using CLSI-recommended quality control strains (3). Both fluoroquinolones and the nonfluoroquinolone agents vancomycin, oxacillin, erythromycin, gentamicin, chloramphenicol, tetracycline, and penicillin were tested. Known quinolone resistance determining regions (QRDRs) for the DNA gyrase subunit genes gyrA and gyrB, the topoisomerase IV subunit genes grlA and grlB (S. aureus) and parC and parE (S. pneumoniae), and the promoter regions of the norA and pmrA efflux pump genes were amplified by PCR and sequenced directly. The primer sequences used for amplicon generation and sequencing are shown in Table 1 .
DQ-113 was less effective than sitafloxacin, moxifloxacin, and levofloxacin in preventing the emergence of single step mutants from the PRSP strains. Sitafloxacin selected singlestep mutants from only two of the five strains, moxifloxacin and levofloxacin selected single-step mutants from three strains, DQ-113 selected single-step mutants from four strains, and ciprofloxacin selected single-step mutants from all five strains. All mutants were selected at mutational frequencies of 10 Ϫ5 to 10 Ϫ7 . DQ-113 was the most potent agent, with all mutants being susceptible to 0.007 g/ml, compared to 0.06 g of sitafloxacin/ml, 0.25 g of moxifloxacin/ml, 2 g of levofloxacin/ml, and 8 g of ciprofloxacin/ml (data not shown). Mutants were selected from all strains after five exposures to subinhibitory drug concentrations and were more resistant. All were inhibited by 0.12 g of DQ-113/ml, 4 g of sitafloxacin/ml, 8 g of moxifloxacin/ml, 64 g of levofloxacin/ml, and 128 g of ciprofloxacin/ml ( Table 2) .
The QRDR sequences of gyrA, gyrB, parC, and parE revealed mutations only in the QRDR of parC and only in 2 of the 20 single-step mutants. No mutations were detected in the promoter of the pmrA gene. Both mutants with QRDR changes had the mutation Ser(79)Tyr. One of these was a double mutant with Glu(120)Asp as its second mutation (data not shown).
DQ-113 was the most effective agent for preventing the emergence of single-step mutants of MSSA and MRSA, with only one mutant selected from the 10 strains compared to mutants being selected from 4 strains by moxifloxacin, 5 strains by sitafloxacin, 7 strains by levofloxacin, and 8 strains by ciprofloxacin. All single-step mutants were susceptible to 0.03 g of DQ-113/ml, 0.25 g of sitafloxacin/ml, 0.5 g of moxifloxacin/ml, 2 g of levofloxacin/ml, and 8 g of ciprofloxacin/ml, with frequencies of 10 Ϫ6 and 10 Ϫ10 , with no apparent differences between the fluoroquinolones (data not shown).
Mutants were selected by subinhibitory drug concentrations from all parents with all mutants inhibited by 2 g of DQ-113/ ml, 16 g of sitafloxacin/ml, 32 g of moxifloxacin/ml, 256 g of levofloxacin/ml, and Ͼ128 g of ciprofloxacin/ml. Reduced susceptibility to gentamicin (four mutants with MICs increasing from 0.12 to 1 g/ml [one mutant], 0.25 to 1 g/ml [two mutants], and 0.25 to 2 g/ml [one mutant]) and chloramphenicol (MIC increased from 4 to 16 g/ml [one mutant]) was detected, and increased susceptibility to erythromycin (0.5 to 0.12 g/ml [two mutants]) and tetracycline (MIC decreased from 1 to 0.25 g/ml [1 mutant]) was detected (data not shown).
Mutations in the single-step mutants occurred in the QRDR of grlA in 17 of the 28 mutants, with the most frequent mutation being Ser(80)Phe. Other mutations were Ser(80)Tyr, Glu(84)Lys, and Pro(144)Ser. A Pro(144)Ser mutation occurred outside the defined QRDR of grlA of a ciprofloxacinselected mutant, which also had a Ser(80)Phe mutation and three point mutations in the 5Јuntranslated region of the norA gene (data not shown).
Single-step mutants of VRE were selected at frequencies of 10 Ϫ5 and 10 Ϫ8 from each strain with each fluoroquinolone except sitafloxacin, which selected mutants from four strains. All mutants were susceptible to 2 g of DQ-113/ml, 4 g of sitafloxacin/ml, 8 g of moxifloxacin/ml, and 16 g of levofloxacin and ciprofloxacin/ml. The mutants selected by subinhibitory concentrations were more resistant than the singlestep mutants, being inhibited by 8 g of DQ-113 and sitafloxacin/ml, 64 g of moxifloxacin/ml, 128 g of ciprofloxacin/ml, and 256 g of levofloxacin/ml. Vancomycin resistance was lost from a ciprofloxacin-selected mutant of E. faecium (MIC decreased from Ͼ128 to 2 g/ml; data not shown).
Overall, DQ-113 was approximately 10-fold or more potent (5) or ABC transporters such PatA and PatB (7, 9) . None of the study fluoroquinolones was highly active against the mutants of vancomycin-resistant E. faecium, suggesting that they would be unsuitable for monotherapy of serious infections caused by this pathogen.
